Takeda Broadens Diabetes Pipeline With PPD Agreement For DPP4 Inhibitors
This article was originally published in The Pink Sheet Daily
Executive Summary
Takeda completes acquisition of development and marketing rights to PPD’s dipeptidyl peptidase IV inhibitors for treatment of type 2 diabetes. PPD will provide clinical development services. The deal follows the discontinuation of Takeda’s in-house novel diabetes agent due to liver abnormalities.
You may also be interested in...
Drug Safety Concerns Create CRO Opportunity, PPD Says
Contract research organizations could see financial opportunities in "more intricate safety monitoring," CEO Eshelman says during earnings call. Regulatory uncertainty accompanies shift in PPD's business away from big pharma, toward biotech firms.
Drug Safety Concerns Create CRO Opportunity, PPD Says
Contract research organizations could see financial opportunities in "more intricate safety monitoring," CEO Eshelman says during earnings call. Regulatory uncertainty accompanies shift in PPD's business away from big pharma, toward biotech firms.
Lilly/Amylin’s Byetta Type 2 Diabetes Therapy To Launch June 1
Amylin will put 325 reps behind exenatide, in addition to a Lilly sales force. The firms will target 60,000 physicians in first six months. First-in-class gut hormone follows approval of Amylin’s diabetes therapy Symlin in March.